Fig. 4

CD39 expression on various murine tumor infiltrating lymphocyte and myeloid populations. (a) CD39 expression on live CD45+ immune cells or CD45- tumor cells from freshly digested MC38 murine tumors (around 100 to 200 mm³) of untreated mice was assessed by flow cytometry. TAMs: CD11b⁺Ly6C⁻Ly6G⁻F4/80⁺; G-MDSC: CD11b⁺Ly6G⁺; M-MDSC: CD11b⁺Ly6C⁺. (b) CD39 expression on Tregs (CD4⁺CD25⁺FoxP3⁺) and non-Tregs (CD4⁺CD25⁻FoxP3⁻) as well as PD-1⁺ or PD-1⁻ CD4 and CD8 T cells was assessed in tumors and tumor draining-lymph nodes (TDLN) of untreated mice. (c)-(e) Mice bearing palpable tumors (50–80 mm³) were injected i.p with the indicated doses of CD39 ASO or with 100 mg/kg of control oligo 1. Day 9 post ASO injection tumors were digested and CD39 expression on tumor infiltrating Tregs/non-Tregs (c), TAMs (d) and CD8 (e) was assessed by flow cytometry. Data is represented as fold-change in CD39 MFI compared to control oligo. In all cases each data point represents a mouse. Pooled data from two to three independent repeats. Error bars indicate SD. Asterisks indicate significant differences compared to control oligo 1 group